What Causes Small Cell Lung Cancer?
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer. Although it accounts for fewer than 20% of all lung cancer diagnoses, it is responsible for a disproportionate number of deaths due to how quickly it spreads.
Understanding what causes SCLC and what the prognosis looks like can help patients and families make more informed decisions about care. Tobacco smoking is the overwhelming cause of SCLC. Unlike non-small cell lung cancer, which also occurs in non-smokers, SCLC is very rarely diagnosed in people who have never smoked. Risk is closely tied to how long a person has smoked and how much.
Additional risk factors include:
- Prolonged secondhand smoke exposure
- Radon gas exposure in homes or workplaces
- Workplace carcinogens such as asbestos, arsenic, or nickel
- Prior radiation therapy to the chest or breast
- A family history of lung cancer
- HIV infection
Symptoms of Small Cell Lung Cancer
SCLC commonly produces no symptoms in its early stages. By the time symptoms appear, the cancer has usually already spread.
Common symptoms include:
- A persistent cough that worsens over time
- Shortness of breath or difficulty breathing
- Chest pain or discomfort
- Coughing up blood
- Hoarseness or voice changes
- Unexplained weight loss and fatigue
- Facial swelling or swollen neck veins
Some patients also experience paraneoplastic syndrome conditions caused by the immune system's response to the tumour, not the tumour itself. These can affect the nervous system or endocrine system and may appear before a formal cancer diagnosis.
How Does Small Cell Lung Cancer Develop?
SCLC begins when lung cells undergo genetic mutations that cause them to divide uncontrollably. These cells clump together to form tumours, which then shed cancer cells into the bloodstream and lymphatic system, often spreading to distant sites long before a diagnosis is made. According to the research, SCLC commonly spreads to the lymph nodes, brain, liver, bones, and adrenal glands.
How Is SCLC Staged?
SCLC is staged differently from non-small cell lung cancer. Clinicians use a simplified two-stage system.
Limited-Stage SCLC
The cancer is confined to one lung and nearby lymph nodes, within a field that can be treated with a single radiation plan. Around 30% of patients are diagnosed at this stage.
Extensive-Stage SCLC
The cancer has spread beyond one lung to the opposite lung, distant lymph nodes, or other organs. Approximately 70% of SCLC patients are diagnosed at this more advanced stage, often because symptoms only emerge once the disease has already progressed significantly.
Prognosis for Small Cell Lung Cancer
The prognosis for SCLC is generally more serious than for non-small cell lung cancer.
For limited-stage disease, the five-year survival rate is approximately 20 to 25%, with a median survival of around 15 to 20 months. For extensive-stage disease, the five-year survival rate is below 5%, though median survival is improving with immunotherapy, now reaching 8 to 13 months for many patients.
A key feature of SCLC is that it initially responds well to chemotherapy and radiation. However, relapse is common, and once the cancer recurs, it tends to be resistant to further treatment. According to research, improving long-term SCLC outcomes remains one of the most significant unmet needs in thoracic oncology.
Treatment Options for SCLC
Treatment for SCLC depends on the stage. Chemotherapy and radiation therapy are the primary approaches.
For limited-stage SCLC, the standard approach combines chemotherapy, typically etoposide with a platinum agent, and chest radiation. Prophylactic cranial irradiation (low-dose radiation to the brain) may also be recommended for patients who respond well to reduce the risk of brain metastases.
For extensive-stage SCLC, chemotherapy remains the cornerstone. Immunotherapy drugs, including atezolizumab and durvalumab, are now approved in combination with chemotherapy for extensive-stage disease and have improved survival outcomes. Surgery is rarely appropriate but may be considered for very early, localised SCLC in a small number of patients.
Conclusion
Small-cell lung cancer is a fast-growing and serious condition, most commonly linked to long-term smoking. It often spreads early, which makes early diagnosis difficult and affects overall outcomes. Treatment, including chemotherapy, radiotherapy, and immunotherapy, can help control the disease and improve quality of life, but prognosis is still limited in many cases. Early detection and a good response to treatment can make a meaningful difference. Supportive care, symptom management, and quitting smoking are all essential parts of treatment and recovery. If you notice persistent symptoms or have risk factors, consult with a pulmonologist for evaluation and guidance on treatment.
